CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.628. It has been cited 21 times, with 17 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0.164
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 17 citers.
National Cancer Institute
Grant: 5-K08-CA-277013
National Cancer Institute
Grant: 5-P01-CA-214278
NCI NIH HHS
Grant: K08 CA286762
NHLBI NIH HHS
Grant: R01 HL178849
NCI NIH HHS
Grant: P01 CA214278
FDA HHS
Grant: R01 FD008168
NCI NIH HHS
Grant: K08 CA277013
NCI NIH HHS
Grant: R37 CA262362
Curing Kids Cancer
American Society of Hematology
Susan S. and Stephen P. Kelly Center for Pediatric Cancer Immunotherapy at Children’s Hospital of Philadelphia
Emily Whitehead Foundation
MeSH Terms
Keywords